Dronabinol

Colorado School of Public Health launched 'Tea on THC', an educational campaign on high-concentration cannabis, funded by the State of Colorado. The campaign focuses on youth and pregnant or nursing mothers, featuring self-paced learning, podcasts, and testimonials from individuals affected by high-THC cannabis use.

Patients with peripheral neuropathy showed improvement in neuropathic pain with cannabis-based medicines, according to a systematic review in The Journal of Hand Surgery. 79% of studies reported positive outcomes, with mild side effects.

Brains Bioceutical Corp. expands its cannabinoid API offerings, including EU-GMP certified CBN, D9-THC in solid crystalline form, and CBG undergoing final validation. These additions support clinical research and therapeutic innovation, building on successful cannabinoid-based medications like Epidiolex, Marinol, and Sativex. The global cannabinoid pharmaceutical market is projected to grow significantly, reflecting increasing recognition of their therapeutic potential.

Avextra Portugal launches an in-house breeding program to develop proprietary cannabis varieties with specific cannabinoid and terpene profiles, aiming for consistency and scalability in pharmaceutical production. Led by industry experts, the program uses 5,000 seeds over two years, with 600 already germinated, focusing on stable cannabinoid output, terpene selection, cultivation environment optimization, and extraction efficiency. This initiative aligns with Avextra’s commitment to advancing safe and effective cannabis-based medicines.

MAPS received FDA approval for a clinical trial examining cannabis' impact on PTSD in veterans, focusing on 'real-world' use and higher THC content.

Denmark's six-year medical cannabis pilot scheme may transition to a fully legalized market, following a government announcement. The pilot, which has seen a 90% growth in prescriptions, aims to become permanent by 2025, with plans to streamline the current four-framework system and standardize licensing and reimbursement processes. The move is expected to expand the market and increase access to treatment, with potential impacts already seen in rising cannabis stocks.

Six years after UK legalized medical cannabis, families demand NHS access due to low prescribing rates. Only 27% of NHS trusts prescribe licensed cannabis medicines, with 1,104 patients receiving such prescriptions in 2023. Contrastingly, 35,000 patients use private sector prescriptions, highlighting a gap in NHS services. Pediatric access remains limited, with only 50 children able to afford private prescriptions. The NHS and Department of Health and Social Care cite limited evidence as a barrier to wider prescription, despite calls for action from the Cannabis Industry Council.

McClure et al. analyzed cannabis use disorder treatment trials, finding that reductions in use, even short of abstinence, significantly improved cannabis-related problems and functional outcomes. A 50% reduction in days of use and 75% in use amounts showed maximum improvements. This challenges the FDA's reliance on abstinence outcomes for medication approval, suggesting that nonabstinence reductions could facilitate new treatment development.

Olanzapine significantly reduced severe nausea in breast cancer patients during chemotherapy, outperforming prochlorperazine. A cannabis extract also showed efficacy in relieving chemotherapy-induced nausea and vomiting, though with more side effects.